湖南九典制药股份有限公司 控股子公司管理制度 第一章 总则 第一条 为促进湖南九典制药股份有限公司（以下简称"九典制药"或"公 司"）的规范运作和健康发展，明确公司与各控股子公司财产权益和经营管理责 任，确保控股子公司规范、高效、有序地经营运作，根据《中华人民共和国公司 法》《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》（以下 简称"《上市规则》"）《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等有关法律法规及《湖南九典制药股份有限公司章程》 （以下简称"《公司章程》"）的规定，结合公司的实际情况，制定本制度。 第二条 本制度所称控股子公司是指公司持有其 50%以上股份的，或者能够 决定其董事会半数以上成员组成，或者通过协议或者其他安排能够实际控制的具 有独立法人资格的公司。 第三条 控股子公司需遵守公司关于公司治理、关联交易、信息披露、财务 管理、募集资金、对外担保等方面的各项管理制度，做到诚信、公开、透明。 第二章 三会管理 第四条 控股子公司应参照《公司法》《公司章程》的相关规定设立股东会、 董事会（或执行董事）及监事会（或监事）。公司主要通过参与控股子公司股 ...

湖南九典制药股份有限公司 募集资金管理办法 第一章 总则 第一条 为了规范湖南九典制药股份有限公司（以下简称"公司""本公司"） 募集资金的管理和运用，最大程度地保障投资者的利益，依据《中华人民共和国 公司法》《中华人民共和国证券法》《上市公司监管指引第 2 号——上市公司募 集资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规和规范性文件及《湖南九典制药 股份有限公司章程》（以下简称"公司章程"）的规定，结合公司实际情况，特 制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票及其衍生品种，向投资 者募集并用于特定用途的资金，但不包括公司实施股权激励计划募集的资金。 第三条 公司董事会应当对募集资金投资项目的可行性进行充分论证，确信 投资项目具有较好的市场前景和盈利能力，有效防范投资风险，提高募集资金使 用效益。 第四条 公司应当建立并完善募集资金存储、使用、变更、监督和责任追究 的内部控制制度，明确募集资金使用的分级审批权限、决策程序、风险控制措施 及信息披露要求。 第五条 公司的董事、监事和高级管理人员应当勤勉尽责，督促上市公司规 范 ...

Financial Performance - The company's operating revenue for 2024 reached ¥2,930,677,498.58, an increase of 8.85% compared to ¥2,692,511,461.24 in 2023[15]. - Net profit attributable to shareholders for 2024 was ¥512,377,174.16, representing a 39.13% increase from ¥368,260,790.68 in 2023[15]. - The cash flow from operating activities for 2024 was ¥746,364,584.85, up 73.10% from ¥431,185,028.10 in 2023[15]. - Basic earnings per share for 2024 were ¥1.05, a 36.36% increase from ¥0.77 in 2023[15]. - Total assets at the end of 2024 amounted to ¥3,373,131,232.71, reflecting a 17.48% increase from ¥2,871,199,809.89 at the end of 2023[15]. - The company achieved a consolidated revenue of CNY 293,067.75 million in 2024, representing an 8.85% increase year-over-year[77]. - The net profit attributable to shareholders reached CNY 51,237.72 million, a 39.13% increase compared to the previous year[77]. - The revenue from drug formulations was CNY 2,357,173,125.6, accounting for 80.43% of total revenue, with a growth of 5.40% year-on-year[91]. Dividend Distribution - The company plans to distribute a cash dividend of 3.10 CNY per 10 shares (including tax) based on a total of 495,896,815 shares[3]. - The cash dividend distribution accounts for 100% of the total distributable profit of RMB 512,377,174.16[188]. - The company has no plans for stock dividends or capital reserve transfers in the current profit distribution proposal[187]. Research and Development - The company is actively pursuing research and development in both pharmaceutical formulations and excipients, aiming to enhance its competitive edge in the market[30]. - The R&D pipeline includes 31 projects, with 14 active pharmaceutical ingredients and 17 excipients, focusing on cutting-edge fields such as oncology and diabetes[56]. - The company has maintained a stable R&D investment of over 10% of revenue for several years, with a research team of over 100 members and a laboratory area exceeding 2,000 square meters[56]. - The company is focusing on expanding its product offerings and enhancing its market presence through new drug registrations and certifications[46]. - The company is committed to continuous improvement in product quality and compliance with GMP standards throughout the production process[38]. Market Position and Strategy - The company anticipates continued stable growth in the pharmaceutical sector through 2025, driven by increasing health awareness and government investment in healthcare[27]. - The company has established a strong presence in over 60 countries, including the US, Japan, and Europe, due to its advanced manufacturing technology and quality assurance systems[29]. - The company is actively pursuing market expansion strategies, targeting new geographic regions to enhance its market presence[136]. - The company is considering strategic acquisitions to bolster its competitive position in the market[136]. - The company has a commitment to quality management, as evidenced by the role of the quality director in the supervisory board[168]. Governance and Compliance - The company has a comprehensive governance structure, including a board of directors and supervisory board[4]. - The company emphasizes the importance of risk awareness regarding forward-looking statements and future plans[3]. - The company adheres to strict governance practices in line with the Company Law and Securities Law, ensuring stable development and protection of investor rights[142]. - The company has established a performance evaluation and incentive mechanism for directors and senior management to ensure fairness and effectiveness in assessments[149]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[140]. Investor Relations - The company has a dedicated investor relations team to handle inquiries and disclosures[12]. - The company held multiple investor meetings throughout 2024, with a total of 301 participants in the April 25 meeting alone[135]. - The company is focusing on expanding its investor relations activities, as evidenced by the diverse range of institutional investors participating in the meetings[135]. - The company is committed to providing detailed insights into its financial and operational conditions during investor interactions[135]. - The company has been proactive in addressing investor inquiries and concerns through various communication channels[135]. Product Development and Innovation - The company has developed high-end excipients, with 103 registered varieties, of which 58 are in A status, particularly excipients for biological vaccines reaching advanced international standards[30]. - The company is actively expanding its product pipeline, with several new drug formulations in the registration process, indicating a commitment to innovation[40]. - The company has registered multiple new excipient products, all of which are in the production application stage[42]. - The company has introduced new products such as Indobufen Tablets and Vildagliptin Tablets, which are included in the National Medical Insurance Drug List[46]. - The company is pursuing a strategy of continuous innovation, as evidenced by the diverse range of products in various stages of development[41]. Risk Management - The company emphasizes quality control through process innovation and compliance management, aiming to enhance product competitiveness[127]. - The company acknowledges the potential for R&D risks due to market demand fluctuations and insufficient funding for product development[130]. - The company recognizes the impact of talent retention on R&D project progress, emphasizing the need for a stable and skilled workforce[131]. - The company is subject to regulatory requirements for drug production licenses, which must be renewed timely to avoid operational disruptions[131]. - The company faces risks related to concentrated procurement policies that may impact sales of key products, such as Loxoprofen Sodium Gel and Pantoprazole Sodium Enteric-Coated Tablets[129]. Environmental and Social Responsibility - The company has received multiple awards for its commitment to safety and environmental protection, including national-level green factory recognition[74]. - The company has implemented wastewater treatment capabilities of 1,200 tons per day and air treatment of 38,000 cubic meters per hour[75]. - The pharmaceutical industry involves complex production processes with significant environmental impacts, and stricter future environmental regulations may increase operational costs[133]. Human Resources - The company has a total of 2,221 employees, with 971 in production, 442 in sales, and 492 in technical roles, reflecting a balanced workforce[183]. - The company emphasizes talent development through a three-tier training system, enhancing employee satisfaction and loyalty[185]. - The company has identified no significant risks during the supervisory activities of the supervisory board in the reporting period[182]. - The company has a dynamic compensation system based on performance, capability assessment, and job value, aiming to motivate employees and align their interests with the company's growth[184].

Financial Performance - The company's revenue for Q1 2025 was CNY 696,028,386.21, representing a 17.79% increase compared to CNY 590,896,382.47 in the same period last year[6] - Net profit attributable to shareholders was CNY 125,775,709.52, a slight increase of 0.08% from CNY 125,669,473.12 year-on-year[6] - Basic earnings per share decreased by 30.56% to CNY 0.25, compared to CNY 0.36 in the same period last year[6] - Total operating revenue for the current period reached ¥696,028,386.21, an increase of 17.76% compared to ¥590,896,382.47 in the previous period[22] - Net profit for the current period was ¥125,775,709.52, slightly up from ¥125,669,473.12, reflecting a marginal increase of 0.08%[23] - The total comprehensive income for the current period was ¥125,775,709.52, slightly higher than ¥125,669,473.12 in the previous period[24] Cash Flow - The net cash flow from operating activities decreased by 38.15% to CNY 147,303,852.15, down from CNY 238,171,199.76 in the previous year[6] - Cash flow from operating activities generated a net amount of ¥147,303,852.15, down 38.19% from ¥238,171,199.76 in the prior period[26] - Net cash flow from investment activities was -$44.91 million, a decrease from -$126.37 million year-over-year[27] - Total cash inflow from financing activities was $56.78 million, compared to $9.00 million in the previous period[27] - Cash and cash equivalents increased by $153.21 million, up from $108.85 million year-over-year[27] - Cash outflow for investment activities totaled $246.16 million, an increase from $126.42 million year-over-year[27] - Cash outflow for financing activities was $5.96 million, compared to $11.95 million in the previous period[27] - Cash inflow from investment activities amounted to $201.25 million, up from $46,000 in the previous period[27] - Cash paid for the acquisition of fixed assets and intangible assets was $66.16 million, down from $86.42 million year-over-year[27] - Cash received from investment income was $1.25 million, unchanged from the previous period[27] Assets and Liabilities - Total assets increased by 3.43% to CNY 3,488,955,041.56 from CNY 3,373,131,232.71 at the end of the previous year[6] - Current assets totaled CNY 1,676,547,724.08, up from CNY 1,601,774,702.04, indicating an increase of about 4.7%[19] - Cash and cash equivalents rose to CNY 588,329,341.07 from CNY 443,307,337.44, marking a significant increase of approximately 32.7%[17] - The company's accounts receivable decreased to CNY 332,261,404.58 from CNY 350,502,639.39, a decline of about 5.2%[17] - Inventory levels remained stable, with a slight decrease from CNY 367,704,817.24 to CNY 366,528,565.07, a change of approximately -0.3%[17] - Total liabilities decreased from CNY 391,863,535.79 to CNY 294,960,082.37, representing a reduction of about 24.7%[19] - Long-term borrowings increased by 43.61% to CNY 183,696,080.00, attributed to stock repurchase loans and project loans[10] - Long-term borrowings increased to CNY 183,696,080.00 from CNY 127,913,000.00, reflecting a growth of approximately 43.6%[19] - Total liabilities amounted to ¥839,592,801.00, a decrease of 0.96% from ¥846,401,371.85[20] - Total equity attributable to shareholders reached ¥2,649,362,240.56, an increase of 4.83% from ¥2,526,729,860.86[20] Research and Development - The company reported a 54.19% increase in R&D expenses, totaling CNY 63,106,394.07, compared to CNY 40,928,107.97 in the previous year[10] - Research and development expenses increased to ¥63,106,394.07, a rise of 54.36% compared to ¥40,928,107.97 in the previous period[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 43,861[12] - The company reported a total of 125,061,391 shares with restricted sales at the end of the period, up from 124,305,686 shares at the beginning[15] Other Information - The company experienced a significant increase of 3330.65% in special reserves, amounting to CNY 295,936.61, due to increased safety investment reserves[10] - The company reported a decrease in other income by 72.23%, totaling CNY 6,907,915.13, primarily due to a reduction in government subsidies received[10] - The company has not disclosed any new product developments or market expansion strategies during this reporting period[16]

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-018 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 2 月 17 日召开 第四届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司通过集中竞价交易方式以自有资金和股票回购专项贷款资金回购部分社会 公众股份，用于后期实施股权激励计划。本次回购的资金总额不低于人民币 10,000 万元且不超过人民币 15,000 万元，回购价格不超过人民币 24.98 元/股， 实施期限为自董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公 司在巨潮资讯网披露的《回购股份报告书》（公告编号：2025-012）等相关公告。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等有关 规定，回购期间公司应当在每个月的前三个交易日内披露截 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-017 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于 2025 年第一季度可转换公司债券转股情况的公告 特别提示： 1、九典转02转股期限为2024年3月21日至2029年9月14日，最新转股价格为 15.33元/股。 2、2025年第一季度，共有383张九典转02完成转股，对应票面金额为38,300 元，转股数量为2,495股。 3、截至2025年第一季度末，九典转02剩余2,053,514张，对应票面金额为 205,351,400元。 根据《深圳证券交易所创业板股票上市规则》有关规定，湖南九典制药股份 有限公司（以下简称"公司"）现将2025年第一季度可转换公司债券（以下简称 "可转债"）转股及公司股份变动情况公告如下： 一、可转换公司债券基本情况 转股期限自 2024 年 3 月 21 日起至 2029 年 9 月 14 日止。 二、可转债转 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2025-016 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于股东减持股份的预披露公告 股东熊英保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 持有本公司股份 720,929 股（占本公司总股本比例 0.145%）的财务总监熊 英女士，计划在本公告披露之日起 15 个交易日后的 3 个月内以集中竞价方式减 持本公司股份不超过 180,232 股（占本公司总股本比例 0.036%）。 公司于近日收到熊英女士出具的《股份减持计划告知函》。现将相关情况公 告如下： 二、本次减持计划的主要内容 | 股东名称 | 减持原因 | 股份来源 | 减持数量及比例 | 减持方式 | 减持期间 | 减持价格 | | --- | --- | --- | --- | --- | --- | --- | | 熊英 | 个人资金 | 公司首次公开 发行前已发行 的股份 ...

编号：2025-08 证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转 02 湖南九典制药股份有限公司 投资者关系活动记录表 |  | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 其他 | | 参与单位名称及 人员姓名 | 招商证券、鹏扬基金、圆信永丰基金机构投资者代表共 4 人 | | 时间 | 2025 年 3 月 25 日上午 10:00-11:00 | | 地点 | 公司会议室 | | 上市公司接待人 | 副总经理兼董事会秘书：曾蕾 | | 员姓名 | 证券事务代表：甘荣 | | | 主要采用解答投资者提问的方式进行，主要问题回复如下： 1、公司如何看待竞品获批对公司的影响？ 回复：对于竞品获批公司将积极应对。在成本端，凭借 | | | 完整的产业链布局，公司能够自主生产原料药和关键辅料， | | | 确保产品质量的同时有效控制成本。在销售端，公司已建立 | | | 起全渠道覆盖体系，特别是院外市场，已成为业绩增长的新 | | 投 ...

证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转 02 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2025-07 |  | 特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 其他 | | 参与单位名称及 | 红思客资产、北斗星投资、诺泉投资、恒盈基金、宇纳资本、 | | 人员姓名 | 唐臣投资等机构投资者及个人投资者共 18 人 | | 时间 | 2025 年 3 月 21 日下午 2:30-4:00 | | | 2025 年 3 月 21 日下午 4:00-5:30 | | 地点 | 公司会议室 | | 上市公司接待人 | 副总经理兼董事会秘书：曾蕾 | | 员姓名 | 证券事务代表：甘荣 首先董事会秘书简要介绍了公司的基本情况，接下来主要采 | | | 用解答投资者提问的方式进行，主要问题回复如下： 1、整个贴膏行业的发展情况是怎样的？ 回复：近年来，贴膏行业在多重因素的推动下呈现出快 | | | 速发展的态势。首先，随着人口老 ...